Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,130.23
(
-0.12%
)
US TECH 100
26,413.00
(
0.42%
)
Dow Jones
48,820.84
(
-0.65%
)
Brent Oil
111.06
(
6.37%
)
Bitcoin
75,539.21
(
-1.06%
)
News Focus
News Focus

Replies to post #218636 on Biotech Values

Replies to #218636 on Biotech Values
icon url

biomaven0

04/20/18 11:06 AM

#218638 RE: randychub #218636

>>RVNC - Can attaching their peptide to other drugs for lasting effect also be in the future?

I really doubt it. It becomes a NCE and so has to go through the full approval process. Easier these days to make some sort of a depot version and go through a 505b2 process.
icon url

DewDiligence

04/20/18 8:07 PM

#218655 RE: randychub #218636

RVNC—Can attaching their peptide to other drugs for [longer]-lasting effect also be in the future?

Even if it could be done technologically, it wouldn’t make sense from a business standpoint, IMO. There are manifold biotech companies who specialize in reformulating existing drugs, so RVNC can almost certainly realize a higher return on investment by focusing on RT002.